Management of comorbid bipolar disorder and substance abuse

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Rates of alcohol and other substance abuse or dependence disorders are substantially higher in persons with bipolar disorders than in the general population, reaching approximately 61% in patients with bipolar I disorder. As a result, clinicians must be prepared to treat substance use disorders and bipolar disorder simultaneously. This presentation reviews data from the 4 published randomized, controlled trials of pharmacotherapy (lithium, carbamazepine, valproate, and quetiapine) in this population. Also reviewed are data from promising open-label, uncontrolled trials. While the results of published research have been generally positive and support the efficacy and tolerability of several agents from different classes in patients with a dual diagnosis of bipolar disorder and substance abuse or dependence, more randomized, controlled research is needed.

Original languageEnglish (US)
JournalJournal of Clinical Psychiatry
Volume67
Issue number8
DOIs
StatePublished - Aug 2006

Fingerprint

Bipolar Disorder
Substance-Related Disorders
Dual (Psychiatry) Diagnosis
Carbamazepine
Valproic Acid
Lithium
Research
Population
Randomized Controlled Trials
Alcohols
Substance Abuse
Drug Therapy

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Arts and Humanities (miscellaneous)
  • Clinical Psychology

Cite this

Management of comorbid bipolar disorder and substance abuse. / Brown, E. Sherwood.

In: Journal of Clinical Psychiatry, Vol. 67, No. 8, 08.2006.

Research output: Contribution to journalArticle

@article{6d103ffb4cfa477193b83fb7c645a5de,
title = "Management of comorbid bipolar disorder and substance abuse",
abstract = "Rates of alcohol and other substance abuse or dependence disorders are substantially higher in persons with bipolar disorders than in the general population, reaching approximately 61{\%} in patients with bipolar I disorder. As a result, clinicians must be prepared to treat substance use disorders and bipolar disorder simultaneously. This presentation reviews data from the 4 published randomized, controlled trials of pharmacotherapy (lithium, carbamazepine, valproate, and quetiapine) in this population. Also reviewed are data from promising open-label, uncontrolled trials. While the results of published research have been generally positive and support the efficacy and tolerability of several agents from different classes in patients with a dual diagnosis of bipolar disorder and substance abuse or dependence, more randomized, controlled research is needed.",
author = "Brown, {E. Sherwood}",
year = "2006",
month = "8",
doi = "10.4088/JCP.0806e05",
language = "English (US)",
volume = "67",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "8",

}

TY - JOUR

T1 - Management of comorbid bipolar disorder and substance abuse

AU - Brown, E. Sherwood

PY - 2006/8

Y1 - 2006/8

N2 - Rates of alcohol and other substance abuse or dependence disorders are substantially higher in persons with bipolar disorders than in the general population, reaching approximately 61% in patients with bipolar I disorder. As a result, clinicians must be prepared to treat substance use disorders and bipolar disorder simultaneously. This presentation reviews data from the 4 published randomized, controlled trials of pharmacotherapy (lithium, carbamazepine, valproate, and quetiapine) in this population. Also reviewed are data from promising open-label, uncontrolled trials. While the results of published research have been generally positive and support the efficacy and tolerability of several agents from different classes in patients with a dual diagnosis of bipolar disorder and substance abuse or dependence, more randomized, controlled research is needed.

AB - Rates of alcohol and other substance abuse or dependence disorders are substantially higher in persons with bipolar disorders than in the general population, reaching approximately 61% in patients with bipolar I disorder. As a result, clinicians must be prepared to treat substance use disorders and bipolar disorder simultaneously. This presentation reviews data from the 4 published randomized, controlled trials of pharmacotherapy (lithium, carbamazepine, valproate, and quetiapine) in this population. Also reviewed are data from promising open-label, uncontrolled trials. While the results of published research have been generally positive and support the efficacy and tolerability of several agents from different classes in patients with a dual diagnosis of bipolar disorder and substance abuse or dependence, more randomized, controlled research is needed.

UR - http://www.scopus.com/inward/record.url?scp=39049177203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049177203&partnerID=8YFLogxK

U2 - 10.4088/JCP.0806e05

DO - 10.4088/JCP.0806e05

M3 - Article

C2 - 17107268

AN - SCOPUS:39049177203

VL - 67

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 8

ER -